ESMO 2023: Ad hoc interim OS study results of ZEJULA® (niraparib) from the NORA Ph 3 study and a post hoc analysis from the Ph 3 PRIME trial of niraparib maintenance therapy to be presented
“Our data presentations at this ESMO Gynaecological Cancers Congress continue to support the clinical profile of ZEJULA ® as a maintenance monotherapy for patients in China for both first-line and recurrent ovarian cancer regardless of biomarker status,” said Rafael Amado, MD, President, Head of Global Oncology Research and Development, Zai Lab. “We remain committed to addressing the urgent need for ovarian cancer treatment options globally.”
Share:
More News
“Initiation of the TEADCO Phase 1b/2 basket trial is another important milestone for the ODM-212 clinical development program and reflects our commitment to patients with difficult-to-treat cancers,” said Professor Outi Vaarala, Executive Vice President, Research & Development at Orion. “Together with the ongoing TEADES study, TEADCO highlights the versatility of
“In this study, tovecimig showed an impressive overall response rate which translated into a clinically meaningful and highly statistically significant improvement in PFS for patients with previously treated BTC. The remarkable 56% reduction in the risk of disease progression is unprecedented in this patient population without an actionable mutation in
“We are encouraged to see taletrectinib (IBTROZI) added to the NCCN Guidelines® for CNS Cancers given its demonstrated high rates of intracranial response that are durable in ROS1+ NSCLC patients with brain metastases,” said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. “Given the prevalence of
Daniel Getts, Ph.D., CEO of CREATE, added “MT-304 is proof of what our platform can do, and what our team can execute. Our mRNA-LNP leadership enables us to move from concept to clinic with remarkable speed. Just last weekend at AACR, we presented compelling preclinical data across our in vivo